BioCentury
ARTICLE | Top Story

Amgen Phase II NHL data

December 11, 2001 8:00 AM UTC

Immunomedics (IMMU) partner Amgen (AMGN) reported interim data from a Phase II trial of 19 patients with non-Hodgkin's lymphoma (NHL), in which the combination of epratuzumab and Rituxan rituximab gave a response in 8 of 15 patients with low-grade NHL. Of these 8 responses, 7 had a complete response, which AMGN said is higher than would be expected for Rituxan monotherapy. Data were presented at the American Society of Hematology meeting in Orlando. ...